Cambridge Medical Trials | Alexandria, LA
Status
Conditions
Treatments
About
The goal of this real-world, multi-center, randomized, outpatient study is to assess the effectiveness of the Biofourmis cloud based BiovitalsHF platform to recommend optimal titration of Guideline-Directed Medical Therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) subjects.
Full description
Patients with heart failure (HF) remain at high risk for hospitalization and death in part due to underuse of guideline directed medical therapy (GDMT). Digital interventions may facilitate rapid initiation, titration and optimization of GDMT but have not been systematically evaluated in randomized control trials. In the AIM-POWER study, we evaluated the safety and efficacy of a novel software medical application, BiovitalsHF, as a strategy to guide remote optimization of GDMT in patients with HF with reduced ejection fraction (HFrEF).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Subjects are eligible to be included in the study only if all the following criteria apply:
Participant not on optimal GDMT for HFrEF per investigator judgement. This would include patients ranging from no treatments for HFrEF to a patient on multiple GDMTs for HFrEF but with at least 1 medication at 50% or less than target dose.
Exclusion criteria
Subjects are excluded from the study if any of the following criteria apply:
Therapy related
Primary purpose
Allocation
Interventional model
Masking
122 participants in 2 patient groups
Loading...
Central trial contact
Trace Brookins
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal